Zydus Lifesciences has announced that the U.S. Food and Drug Administration (USFDA) has granted final approval for Indocyanine Green for Injection, USP, 25 mg/vial, with eligibility for 180-day Competitive Generic Therapy (CGT) exclusivity. The approval represents an important milestone for the company, reflecting its continued focus on expanding its portfolio of complex injectable generic medicines while addressing areas with limited generic competition. Under the CGT pathway, the first approved applicant receives a period of market exclusivity following commercial launch, encouraging the development of generic medicines for products with inadequate competition.
Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has emerged as an important therapeutic option for type 2 diabetes mellitus (T2DM). While clinical trials have established its efficacy, real-world evidence describing prescribing behavior and dose utilization after market introduction remains limited. This study assessed outpatient dispensing patterns and changes in tirzepatide strength mix in Japan using nationwide administrative claims data.
Interindividual variability in antihypertensive drug response presents a major challenge in achieving optimal blood pressure (BP) control. Pharmacogenomics (PGx) offers an opportunity to individualize therapy by identifying genetic variants associated with differential drug efficacy and metabolism. This study evaluated the association of a calcium channel blocker (CCB)-related PGx-guided treatment strategy with BP outcomes and short-term safety in Chinese patients with hypertension through a secondary exploratory analysis of two randomized cohorts.
Lupin Limited has announced the U.S. Food and Drug Administration (FDA) approval and commercial launch of Sugammadex Injection, reinforcing its presence in the U.S. hospital injectable market. Sugammadex is a selective neuromuscular blockade reversal agent used to rapidly reverse the effects of rocuronium bromide and vecuronium bromide during surgical procedures. The approval follows the company’s earlier tentative approval and enables commercial availability in the United States.
The Recovery Effects After Semaglutide Termination (REST) trial is a prospective, randomized, open-label clinical study designed to investigate the physiological and cardiometabolic consequences of discontinuing semaglutide therapy in individuals with obesity. Although semaglutide has demonstrated substantial and sustained weight reduction together with improvements in cardiometabolic risk factors, there is limited evidence regarding the optimal strategy for treatment discontinuation. Previous studies have shown that stopping semaglutide is frequently associated with weight regain and reversal of metabolic benefits, highlighting obesity as a chronic disease that may require long-term pharmacological management.
